Praxis Bioresearch Presents Phase 0 Clinical Data for PRX-P4-003 at 14th Annual CTAD conference
Retrieved on:
Tuesday, November 9, 2021
Schedule 2, Gastrointestinal tract, Praxis, ADHD, Binge eating disorder, AD, Attention deficit hyperactivity disorder, Los Angeles, National, Alzheimer's disease, United States patent law, Apathy, LLC, Human, Clinical trial, National Institute of Mental Health, Prescription, Research, GLOBE, Therapy, Methylphenidate, Absorption, US, Amphetamine, Central nervous system, FCF, Risk, FDA, Narcolepsy, Pharmaceutical industry
LOS ANGELES, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Praxis Bioresearch reports Clinical Phase 0 study data (PBR001) to demonstrate the desired pharmacokinetic profile for its lead product candidate, PRX-P4-003 in healthy volunteers (NCT04638803).
Key Points:
- LOS ANGELES, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Praxis Bioresearch reports Clinical Phase 0 study data (PBR001) to demonstrate the desired pharmacokinetic profile for its lead product candidate, PRX-P4-003 in healthy volunteers (NCT04638803).
- The PBR001 data are being reported in a virtual poster presentation format at the 14th Clinical Trials on Alzheimer's Disease (CTAD) meeting, being held November 9-12, in Boston, MA.
- PRX-P4-003 is a new chemical entity (US Patent 10,662,146) designed by Praxis to provide a once-a-day drug to treat apathy caused by Alzheimers disease.
- Praxis Bioresearch, LLC, is a biopharmaceutical company focused on the discovery and development of therapeutics for chronic neuropsychiatric and neurodegenerative disorders.